Royalty Pharma plc (RPRX) Financial Statements

Royalty Pharma plc

RPRX · Nasdaq

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$2.38B	$2.26B	$2.35B	$2.24B	$2.29B	$2.12B	$1.81B	$1.79B
Research & Development	$452.00M	$2.00M	$52.00M	$177.11M	$200.08M	$26.29M	$83.04M	$392.61M
Selling, General & Administrative	$573.48M	$236.67M	$249.75M	$227.30M	$182.83M	$181.72M	$103.44M	$61.91M
Operating Expenses	$818.67M	$971.13M	$862.40M	$1.93B	$858.75M	$526.95M	-$808.92M	$430.45M
Operating Income	$1.56B	$1.29B	$1.49B	$307.06M	$1.43B	$1.60B	$2.62B	$1.36B
Interest Expense	—	—	$187.19M	$187.96M	$166.14M	$157.06M	$268.57M	$279.96M
Other Income / (Expense)	-$235.33M	$38.37M	$207.94M	-$77.00M	-$189.51M	$106.56M	-$161.76M	$153.41M
Income Before Taxes	$1.32B	$1.33B	$1.70B	$230.06M	$1.24B	$1.70B	$2.46B	$1.52B
Provision for Income Taxes	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	$770.95M	$858.98M	$1.13B	$42.83M	$619.73M	$975.04M	$2.35B	$1.38B
Basic EPS	$1.79	$1.92	$2.54	$0.10	$1.49	$1.32	—	—
Diluted EPS	$1.78	$1.91	$2.53	$0.10	$1.49	$1.32	—	—
Basic Shares Outstanding	429.80M	448.19M	447.60M	437.96M	414.79M	375.44M	—	—
Diluted Shares Outstanding	564.46M	594.11M	602.90M	437.97M	414.80M	375.45M	—	—

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$5.32	$5.28	$5.36	4	↑2 ↓0
Dec 2027	$5.53	$5.01	$5.84	4	↑0 ↓1
Dec 2028	$6.19	$5.86	$6.52	2	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: RPRX
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Key Issues

Bullish view

Adjusted EBITDA increased to $736 million from $633 million, while quarterly earnings and revenue exceeded estimates by 3.94% and 1.52%. That supports a view that underlying operating performance remains strong despite lower reported net income.

Bearish view

Net income attributable to Royalty Pharma declined to $18 million from $32 million. Investors may therefore question whether the stronger adjusted EBITDA meaningfully translates into bottom-line earnings.

Analyst Consensus

See all

Buy

7 analysts

$60

Current

—

Low

$66

Average

—

High

Average target implies +10.78% versus the current price.

Earnings History

BeatMissNo estimate

Royalty Pharma plc

Analyst Estimates

Peers